Metropolis Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare's board approved audited Q4 and FY25 results (ended March 31, 2025) with a clean, unmodified opinion from auditor BSR & Co. LLP. Standalone revenue grew ~10.2% YoY to Rs. 1,21,654 lakhs and PAT rose ~7.7% to Rs. 12,479 lakhs, while consolidated revenue grew ~10.2% to Rs. 1,33,120 lakhs with PAT up ~13.3% to Rs. 14,551 lakhs. EBITDA/PBT margin showed mild compression compared to last year, partly due to higher depreciation and other expenses. The company completed the 100% acquisition of Core Diagnostics for Rs. 21,888 lakhs in March 2025, funded via cash and preferential share allotment. Key board decisions include re-appointment of Ameera Shah as Chairperson & Whole-time Director (5 years from March 2026), elevation of Surendran Chemmenkotil from CEO to Managing Director, and appointment of Rehan Khan as Independent Director. The board also approved a new ESOP 2025 and RSU 2025 plan, and appointed Manish Ghia & Associates and PwC as secretarial and internal auditors respectively.
A clean audit and double-digit revenue growth support investor confidence, though margin compression and the sharp Q4 standalone PAT dip (~25% YoY) may temper near-term sentiment. The Core Diagnostics acquisition expands scale but brings integration risks and increased leverage; approval of new ESOP/RSU plans may cause mild dilution. Management continuity with Shah and the MD elevation should provide stability, likely positive for the stock in the medium term.